2009

Pfizer’s Power on Individualized Medicine

September 15, 2009

In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s genome is sequenced and drug prescriptions are based on your genetic makeup, and argues that personalized medicine will be the defining paradigm for discovering and developing drugs of the future. To put these videos into [...]

Read the full article →

Introducing DCbiotech — High-level networking in the nation’s capital

September 3, 2009

DCbiotech is a high-level networking group based in Washington DC. The objective is to bring together individuals working in, or serving, the biotechnology sector in Washington DC. For more information, please visit http://www.DCbiotech.com . The first meeting is scheduled for September 15th. Full details and the RSVP form are available here.

Read the full article →

Drug Patent Expirations in September 2009

September 1, 2009

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in September 2009 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration FARESTON Gtx Inc toremifene citrate 4,696,949 Sep 29, 2009 FELBATOL Meda Pharms felbamate 4,978,680 Sep 26, 2009 FELBATOL Meda Pharms felbamate 5,082,861 Sep 26, 2009 GLUCOTROL XL Pfizer glipizide 5,024,843 Sep [...]

Read the full article →

Biotechnology green shoots?

August 26, 2009

With two life science IPOs earlier this month, and seemingly fewer stories of biotechnology firm liquidations, it seems that the tides are turning — ever so slightly — in the favor of biotechnology.

Read the full article →

Jim Greenwood on Data Exclusivity and Healthcare Innovation

August 13, 2009

Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic drugs. The video appears below. Interestingly, he used the Aspirin vs. Epogen comparison from my book, Building Biotechnology, when he was explaining the difference between small molecule and biologic drugs to members of congress.

Read the full article →

The impact of the global financial crisis on biotechnology development

August 11, 2009

My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic [...]

Read the full article →

Drug Patent Expirations in August 2009

August 4, 2009

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in August 2009 *Drugs may be covered by multiple patents

Read the full article →

Naturally Obsessed: The Making of a Scientist

July 27, 2009

Guest content from Naturally Obsessed Naturally Obsessed: The Making of a Scientist A documentary about careers in science “So what is it that you actually do, Dr. Rifkind?” (groan, groan) It didn’t matter if the question was from my accountant, my dinner party companion or my cousin Minnie, I was never able to give an [...]

Read the full article →

Drug Patent Expirations in July 2009

July 1, 2009

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in July 2009

Read the full article →

Journal of Commercial Biotechnology — July 2009 issue now available

June 22, 2009

The July 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper: Volume 15, Issue 3 Editorial The impact of the global financial crisis on biotechnology development PDF Yali Friedman Commentary Can genetic engineering prevent food-poisoning? PDF Henry Miller Articles Bottom line [...]

Read the full article →

← Previous Entries

Next Entries →